Relative and absolute cancer risks among Nordic kidney transplant recipients—a population‐based study

• Published in: Transplant international Vol. 33; no. 12; pp. 1700 - 1710
• Main Authors: Benoni, Henrik, Eloranta, Sandra, Dahle, Dag O., Svensson, My H.S., Nordin, Arno, Carstens, Jan, Mjøen, Geir, Helanterä, Ilkka, Hellström, Vivan, Enblad, Gunilla, Pukkala, Eero, Sørensen, Søren S., Lempinen, Marko, Smedby, Karin E.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2020; John Wiley and Sons Inc
• Subjects: Cancer; Confidence intervals; Health risks; incidence; Kidney cancer; Kidney transplantation; Kidney transplants; Kidneys; Lung cancer; Lymphoma; malignancy; Medicin och hälsovetenskap; Non-Hodgkin's lymphoma; Original; Population studies; Population-based studies; risk; Risk assessment; Skin cancer; Transplantation; Vigilance; cancer; risk; malignancy; incidence; transplantation
• ISSN: 0934-0874; 1432-2277; 1432-2277
• DOI: 10.1111/tri.13734

Summary Kidney transplant recipients (KTRs) have an increased cancer risk compared to the general population, but absolute risks that better reflect the clinical impact of cancer are seldom estimated. All KTRs in Sweden, Norway, Denmark, and Finland, with a first transplantation between 1995 and 2011, were identified through national registries. Post‐transplantation cancer occurrence was assessed through linkage with cancer registries. We estimated standardized incidence ratios (SIR), absolute excess risks (AER), and cumulative incidence of cancer in the presence of competing risks. Overall, 12 984 KTRs developed 2215 cancers. The incidence rate of cancer overall was threefold increased (SIR 3.3, 95% confidence interval [CI]: 3.2–3.4). The AER of any cancer was 1560 cases (95% CI: 1468–1656) per 100 000 person‐years. The highest AERs were observed for nonmelanoma skin cancer (838, 95% CI: 778–901), non‐Hodgkin lymphoma (145, 95% CI: 119–174), lung cancer (126, 95% CI: 98.2–149), and kidney cancer (122, 95% CI: 98.0–149). The five‐ and ten‐year cumulative incidence of any cancer was 8.1% (95% CI: 7.6–8.6%) and 16.8% (95% CI: 16.0–17.6%), respectively. Excess cancer risks were observed among Nordic KTRs for a wide range of cancers. Overall, 1 in 6 patients developed cancer within ten years, supporting extensive post‐transplantation cancer vigilance.